About Andrew Fradkin
Form D filings for Thylacine Biotherapeutics in 2023 list Andrew Fradkin as secretary and general counsel, director.
Andrew Fradkin first appears on SEC filings in 2023.
Experience
This experience comes from SEC filings. The years are when the filings name Andrew Fradkin in the role, so the role may have started earlier or lasted longer.
Key Colleagues at Startups
The people Andrew Fradkin works with at each company, as listed on that company's latest Form D.
Thylacine Biotherapeutics Inc · Form D, Jan 19, 2023
RG
Robert Graifman
Director
DG
Daniel Graifman
Executive officer and director